- Home
- CLB vs PHVS Comparison
CLB vs PHVS Comparison
Compare CLB & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLB
- PHVS
- Stock Information
- Founded
- CLB 1936
- PHVS 2015
- Country
- CLB United States
- PHVS Netherlands
- Employees
- CLB N/A
- PHVS N/A
- Industry
- CLB
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- CLB
- PHVS Health Care
- Exchange
- CLB Nasdaq
- PHVS Nasdaq
- Market Cap
- CLB 951.4M
- PHVS 1.0B
- IPO Year
- CLB 1995
- PHVS 2021
- Fundamental
- Price
- CLB $19.50
- PHVS $20.35
- Analyst Decision
- CLB Sell
- PHVS Buy
- Analyst Count
- CLB 4
- PHVS 6
- Target Price
- CLB $17.00
- PHVS $35.67
- AVG Volume (30 Days)
- CLB 344.3K
- PHVS 80.9K
- Earning Date
- CLB 10-23-2024
- PHVS 11-13-2024
- Dividend Yield
- CLB 0.20%
- PHVS N/A
- EPS Growth
- CLB N/A
- PHVS N/A
- EPS
- CLB 0.54
- PHVS N/A
- Revenue
- CLB $522,821,000.00
- PHVS N/A
- Revenue This Year
- CLB $4.59
- PHVS N/A
- Revenue Next Year
- CLB $5.11
- PHVS N/A
- P/E Ratio
- CLB $36.15
- PHVS N/A
- Revenue Growth
- CLB 2.68
- PHVS N/A
- 52 Week Low
- CLB $13.82
- PHVS $15.00
- 52 Week High
- CLB $25.13
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- CLB 49.03
- PHVS 43.75
- Support Level
- CLB $20.41
- PHVS $19.78
- Resistance Level
- CLB $21.65
- PHVS $25.40
- Average True Range (ATR)
- CLB 0.73
- PHVS 1.45
- MACD
- CLB -0.01
- PHVS -0.53
- Stochastic Oscillator
- CLB 24.45
- PHVS 9.97
About CLB Core Laboratories Inc.
Core Laboratories is the premier provider of reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
About PHVS Pharvaris N.V.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .